Baseline characteristcs and outcomes | |||||||
> 180 days | |||||||
Parenteral | Oral | ||||||
Interferon beta 1a | Interferon beta 1 b | Glatiramer | Fingolimod | Teriflunomide | |||
Avonex® | Rebif® | Betaferon® | Extavia® | Copaxone® | Gilenya® | Aubagio® | |
N^ pat | 43 | 51 | 14 | 14 | 50 | 37 | 20 |
Median age in years Min – Max | 48 20 – 65 | 41 22 – 65 | 45 24 - 66 | 51 38 - 69 | 45.5 21 - 68 | 46 24 – 57 | 48.5 32 – 67 |
Male gender, % | 23.26 | 27.45 | 42.86 | 42.86 | 30 | 21.66 | 40 |
WRDD (SD) | 3.97 (0.62) | 14.53 (4.46) | 3.32 (0.85) | 3.24 (0.85) | 18.09 (3.27) | 0.45 (0.07) | 11.72 (2.32) |
Cost per RDD (€) | 22.82 | 37.97 | 13.66 | 14.17 | 21.51 | 44.00 | 21.89 |
WADH (SD) | 0.91 (0.13) | 0.81 (0.19) | 0.83 (0.21) | 0.81 (0.21) | 0.90 (0.15) | 0.89 (0.13) | 0.83 (0.16) |
WADH male (SD) | 0.90 (0.16) | 0.86 (0.14) | 0.91 (0.12) | 0.77 (0.30) | 0.93 (0.08) | 0.94 (0.05) | 0.79 (0.19) |
WADH female (SD) | 0.92 (0.12) | 0.79 (0.21) | 0.77 (0.25) | 0.84 (0.13) | 0.88 (0.18) | 0.88 (0.19) | 0.86 (0.14) |